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Introduction. A lack of suitable veins can cause serious problems when attempting to revascularise critically ischaemic legs.
Prosthetic grafts have much worse patency in the femocrural position, despite the use of distal anastomotic cuffs. The use of
adjuvant AV-fistula at the distal anastomosis should increase the graft flow above the thrombotic threshold velocity and thus
increase prosthetic graft patency.
Aim. The aim of the study was to evaluate the benefit of an adjuvant AV-fistula on the patency of a femorocrural PTFE
bypass with a distal vein cuff.
Materials and methods. This prospective randomised multicentre trial was conducted in four centres. A total of 59
patients with critical leg ischaemia and no suitable veins for grafting were randomised to receive a femocrural PTFE bypass
and distal vein cuff, with or without an adjuvant AV-fistula. Thirty-one patients were randomised to the AV-fistula group
(AVFG) and 28 to the control group (CG). Six patients were lost to follow-up during the 2-year study time.
Results. There were six immediate occlusions in each treatment group, but half of these were saved by re-operation. The
mean postoperative ankle-bachial index (ABI) was 0.85 in the AVFG and 0.94 in the CG. The primary and secondary
patency rate at 2 years was 29 and 40% for the AVFG and 36 and 40% for the CG (NS). Leg salvage at 2 years was 65 and
68%, respectively (NS).
Conclusion. Adjuvant AV-fistula does not improve the patency of a femorocrural PTFE bypass with a distal vein cuff.
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Introduction
Prosthetic bypass may be an alternative to primary
amputation for limb salvage in patients with critical
leg ischaemia and no suitable autologous vein.1 – 6
However, the patency of prosthetic bypass is inferior
to that of vein. Vein cuff interposition has been
reported to be beneficial in femorocrural PTFE
reconstructions.7 – 11 The patency is, however, often
threatened by a limited outflow. Sauvage first hypoth-
esised the thrombotic threshold velocity (TTV), a
velocity below which thrombosis occurs.12 Vein cuffs
may reduce the mismatch in compliance between the
recipient artery and the prosthetic graft and alter the
flow characteristics at the anastomosis, thus reducing
myointimal hyperplasia. However, they do not
improve graft flow. An adjuvant AV-fistula may
elevate the flow velocity above the thrombotic
threshold. It has been previously postulated that an
adjuvant AV-fistula might have a beneficial effect on
the patency of a femorocrural PTFE bypass by
increasing blood flow above the thrombotic threshold.
This Scandinavian multicentre pilot trial was
undertaken to compare 6 mm PTFE graft with distal
vein cuff and adjuvant AV-fistula with similar graft
without a fistula. The aim was to determine whether
an adjuvant AV-fistula improved the 2-year outcome
and if so, how large a patient sample would be needed
to prove its superiority.
Materials and Method
Patients
This was a prospective randomised study that was
carried out during the years 1997–2002 in four
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Scandinavian centres (Table 1). Fifty-nine patients
were recruited and randomised between February
1997 and May 2000 according to a block randomisation
stratified by the centre. The inclusion criteria were
patients with critical leg ischaemia (rest pain, ulcers or
gangrene) requiring femorocrural bypass, without a
suitable vein for grafting. Patients were excluded from
the study if they had only claudication, or if the bypass
was to the popliteal or pedal artery.
The average age of the patients was 73.7 years
(range 46–93 years). Fifty-eight percent of the patients
were females. Forty-one percent had diabetes and 61%
coronary artery disease (Table 2). Forty (68%) patients
had distal ischaemic lesions with mean ABI of 0.30 and
0.36, respectively (Table 3). Seventy-one percent of the
patients had had previous vascular surgery and in 34
(58%) cases the prosthetic bypass was a redo-pro-
cedure.
The haemodynamic severity of the ischaemia was
assessed using Doppler ankle/brachial pressure index
(ABI) and the morphology of the obliterative disease
was assessed by digital subtraction angiography. The
run-off score was evaluated preoperatively by the
standards proposed by the Ad Hoc.13 The run-off was
evaluated both for the recipient crural artery and for
pedal arch. Eight patients had inadequate angio-
graphic data that did not allow outflow scoring.
Surgical procedure
There were 39 patients on antiplatelet and six on
anticoagulation therapy preoperatively. All patients
were heparinized during operation. All patients
received oral antiplatelet therapy (ASA) postopera-
tively unless contraindicated, or the patients were
already on anticoagulants for concomitant disease.
Antibiotic prophylaxis of both vancomycin and
cefuroxime or the latter alone was given to all patients.
The surgical procedure was carried out with a 6 mm
externally supported PTFE prosthesis (Gore or Impra
Corp). An interposition vein cuff of the Miller type14
(33), St Mary’s Boot15 (19) or a modified Miller type (7)
was constructed at the distal anastomosis. Patients
randomised to the AVFG received an AV-fistula of the
common ostium type in 25 cases and the proximal type
in six cases according to the surgeon’s discretion. Any
surgeon with previous experience of three AV-fistulas
or more was accepted as an operator.
Follow-up and statistics
The follow-up time was 2 years. Clinical examination
and vascular laboratory visits took place at 7 days, 1, 3,
6, 9, 12, 18 and 24 months postoperatively. A sustained
ABI increase of.0.15 was accepted as an indication of
patency. When in doubt, a duplex scan was performed
to assess patency. Routine duplex evaluation took
place at the one-year follow-up visit. Clinical status,
patency and complications were registered.
Primary and secondary patency, leg salvage and
patients alive with a leg were calculated by the Life
Table method and the Log-Rank test was used to
compare the two groups. The dependency of graft
patency on the patency of the fistula was analysed at
one year by Fisher’s exact test. The study protocol was
approved by the local ethics committees.
Results
Thirty-one patents were randomised to the AV-fistula
group (AVFG) and 28 to the control group (CG). The
two treatment groups were comparable in terms of
Table 1. Centrewise distribution of the patients and severity of their diseases.
Centre No. of patients Mean ABI Run-off AVF group Run-off control group
Helsinki 37 0.37 7.25 (2–10) 5 (2–8.5)
Lappeenranta 13 0.34 6 (3–9) 5.5 (4–7)
Va¨stera˚s 8 0.11 5.5 (1–5.5) 5.25 (1–6)
Hillerod 1 0.43 1 –
Total 59 0.33 6 (1–10) 5 (1–8.5)
ABI (mean) and run-off (median, range, scale 1–10). AVF group, group with adjuvant AV-fistula; control group, group without adjuvant AV-
fistula.
Table 2. Clinical data of the patients as related to the treatment
group.
Clinical characteristic AVF group Control group
Age: mean, (range) 74.3 (49–93) 73 (46–88)
Sex: male/female 15/16 10/18
Diabetes 12 (39%) 12 (43%)
Hypertension* 15 (48%) 14 (50%)
Coronary artery disease 22 (71%) 14 (50%)
Cerebrovascular disease 6 (19%) 8 (29%)
Pulmonary disease 6 (19%) 2 (7%)
Renal failure† 2 (6%) 2 (7%)
Smoking 9 (29%) 12 (43%)
*Blood pressure .160/95 mmHg or medication.
†Level of serum creatinine .150 mmol/l.
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their demographics, as well as the indications for
surgery, the outflow artery and preoperative ABI
values.
There were no perioperative deaths. There were 12
(20%) immediate graft occlusions (,30 days), six in
the AVFG and six in the CG. Nine of these underwent
re-operation, which was successful in six grafts but
three required amputation. Of the three non-reoper-
ated patients, direct amputation was chosen in one
case during the immediate post-operative period. In
two cases conservative treatment was chosen leading
to amputation at 9 months in one case and leg salvage
at 2 years in the other case. In one case amputation
required with a patent graft due to severe foot
gangrene. The median ABI increase from the pre-
operative level was 0.55 in the fistula group and 0.57 in
the control group at 1 month (Table 4). The median
duration of the operation was 222 min in the AVFG
and 179.5 min in the CG ðp ¼ 0:04Þ:
Immediate postoperative complications were
encountered in 24 patients, half of which were
wound problems. Nine patients had general compli-
cations and all recovered (Table 5). Two superficial
wound infections required revision of the wound,
which led to healing of the infection and the others
were treated conservatively. There were two compart-
ment syndromes treated by fasciotomy following
surgery. There was one immediate graft infection,
which was cured by revision and a sartorius muscle
flap, but the patient died of a myocardial infarction at 6
weeks.
There were six withdrawals during the 2-year
surveillance. One drop out was at 3 months with a
patent graft. One patient had an occluded graft at 15
months with no later record. Four patients were
followed up to 18 months at which time two of the
grafts were patent and two occluded. Ten percent
(17%) patients died during the study. In six cases
where the cause of death was known, it was not
directly related to the surgery.
There were 24 late graft occlusions. In 13 cases re-
operation was attempted. Secondary patency was
achieved in three cases with thrombectomy and graft
revision and in three cases the graft occluded despite
additional procedures. Seven cases required a redo-
procedure. The cumulative primary and secondary
patencies were 29 and 40% in the AVFG and 36 and
40% in the CG. The primary and secondary patencies
were similar (p ¼ 0:77 and 0.89), irrespective of the
presence or absence of the fistula (Figs. 1 and 2).
There were 13 amputations after the initial 30-day
period, eight in the AVFG and five in the CG. Below-
knee amputation was performed in four cases and
above-knee in nine cases. Leg salvage and patients
alive with a leg at 2 years were not affected by the
operative technique chosen (Figs. 3 and 4, p ¼ 0:97 and
0.60).
Late complications were encountered in four
patients. One patient had a superficial wound infec-
tion at 3 months, which resolved. There was one late
graft infection following thrombosis of the graft. The
infection led to removal of the prosthesis and crural
amputation at 9 months. The patient died at 10 months
from myocardial infarction. One patient developed a
MRSA-infection following occlusion and a redo-
procedure. In another redo-procedure, cuff disruption
was successfully treated by direct suture. One patient
developed venous hypertension: oedema and static
eczema related to the AV-fistula. The symptoms
resolved after closure of the fistula at 3 months. The
graft remained patent after the additional procedure.
Nineteen patients with AV-fistula were available for
Table 3. Indication for surgery, outflow vessel and preoperative
ABI in AVF- and control group.
Indication AVF group Control group
Rest pain 8 11
Ulcers 16 14
Gangrene 7 3
A.tibilalis anterior 13 13
A.tibialis posterior 8 7
A.fibularis 10 8
ABI (mean)* 0.30 0.36
*Two patients with erroneous pressure readings due to media-
sclerosis were excluded.
Table 4. Immediate results of the AVF- and control group.





ABI increase (mean)* 0.55 0.57
*Four patients with erroneous pressure readings due to media-
sclerosis were excluded.
Table 5. Immediate complications in AVF- and control group.
Complication AVF group Control group Total
Wound problem 12
Superficial infection 6 4 10
Lymph leakage 2 – 2
Compartment syndrome 1 1 2
Graft infection 1 – 1
General complication 9
Prolonged intensive care 1 1 2
Heart insufficiency 2 2 4
Pneumonia – 1 1
Pulmonary embolism 1 – 1
Deep vein thrombosis – 1 1
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Fig. 1. Primary patency in subgroups of patients with
femorocrural PTFE bypasses with AV-fistulas ¼ AVF group
(…) and without AV-fistulas ¼ control group (—).
Fig. 2. Secondary patency in subgroups of patients with
femorocrural PTFE bypasses with AV-fistulas (…) and
without AV-fistulas (—).
Fig. 3. Leg salvage in subgroups of patients with femor-
ocrural PTFE bypasses with AV-fistula (…) and without AV-
fistula (—).
Fig. 4. Patients alive with leg in subgroups of patients with
femorocrural PTFE bypasses with AV-fistula (…) and with-
out AV-fistula (—).
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duplex evaluation at 1 year. Out of the original 31
AVFG, four were amputated, three dead, three had
occluded grafts and two patients were not available
for surveillance. In all other cases, the patency of the
AV-fistula was confirmed. In six cases, there was an
occlusion of the AV-fistula and in only one case did
this result in graft thrombosis, which after re-operation
led to leg salvage. In one case where the fistula
occluded a revision was done for threatened graft
failure and this also resulted in leg salvage. There were
five patients who had a record of a previously patent
AV-fistula but had graft failure at 1 year. Two of these
patients were re-operated and in three the occlusion
led to amputation. This fistula patency data indicates
that the patency of the graft is not dependent on the
patency of the fistula ðp ¼ 0:02Þ:
Discussion
The results of previous series of femorocrural pros-
thetic bypasses are difficult to compare to our results.
Most studies are retrospective case series without
controls, different adjunctive methods, different types
of patient groups and different prostheses. Dardik et al.
reported a series of 281 patients with femorocrural
bypasses operated between 1979 and 1995 with a 3-
year secondary patency rate of 61% and limb salvage
of 74% using human umbilical vein and an adjunctive
AV-fistula.16,17 Jacobs has reported patency rates of
64–71% at one year and leg salvage rates of 72% with a
PTFE bypass and an AV-fistula.18,19 Kreienberg com-
pared AV-fistula with vein cuff in below knee popliteal
and tibial bypasses and found patency rates of 48 and
38%, respectively.20 Vein cuff seemed to give better
limb salvage rates than AV-fistula (92% vs 76% at three
years). Moody et al. reported a patency rate of 39% at
two years with human umbilical vein plus an AV-
fistula and Eagleton et al. found no statistical difference
between direct prosthetic anastomosis, vein cuff and
AV-fistula (patency rates of 35–65% and limb salvage
of 56–76% in femoro-infrapopliteal bypasses).21,22
Harris et al. suggested an improved outcome with
the combined use of an AV-fistula and a vein cuff.23 Yet
the only previous controlled trial where an AV-fistula
was combined with a vein cuff is from Hamsho et al.
They reported primary patency rates of 55 and 53% in
both groups and leg salvage rates of 43–54% at one
year.24 Our results are in accordance with these results.
The relatively small number of patients in this study
risks a type two error. However, even if a larger study
showed a statistical difference, it would not be
clinically relevant.
Our results emphasise that early graft revision
yields better secondary patency than late re-operations
as a redo-procedure was often required after late graft
revision. Only half of the late graft occlusions resulted
in re-operation in our series. This shows that these
patients may tolerate graft failure even though the
indication was critical ischaemia. This is a well-known
phenomenon especially in legs with healed skin
lesions. Furthermore critical ischaemia does not
inevitably lead to amputation.25 The effect of re-
operation on patency is clear as shown by the
difference between primary and secondary patency
and, therefore, the role of re-operation must be
emphasised.
If the AV-fistula is constructed to achieve flow
above TTV, it can be postulated that the occlusion of an
adjuvant AV-fistula would result in graft thrombosis.
In our series, a large proportion of grafts stayed open
despite the occlusion of the fistula. This finding
emphasises the lack of benefit on prosthetic graft
patency.
High output cardiac failure, venous hypertension
and steal effect are described as possible complications
of an AV-fistula. In our study we only had one patient
with symptoms of venous hypertension. In our
previous experience, we have had one patient with
cardiac failure due to an adjuvant AV-fistula.26 In this
case the cardiac overload was caused by a too large
fistula with a flow of 1000 cm/s. We did not encounter
steal effects in these patients as they all had uncom-
promised inflow. The ABI increase in both groups was
similar also indicating that in fact the AV-fistula did
not cause a steal effect from the distal circulation. A
substantial increase in the ABI for both groups
reflected the improved distal circulation.18
In summary, an AV-fistula does not improve the
patency of PTFE femorocrural bypass grafts with a
distal interposition vein cuff. Furthermore, it increases
the operation time and the technical challenge.
Appendix
ScanPAC Study Group (Scandinavian Prosthesis, AV-
fistula and Cuff Study).
Co-ordinating centre: Mauri Lepa¨ntalo and Aarno
Lehtola, Helsinki.
Data sampling and analysis: Anita Ma¨kela¨ and
Katariina Laurila, Helsinki.
Statistical aid: Leo Ihlberg, Anders Alba¨ck, Hel-
sinki.
Study centres:
Helsinki: M Lepa¨ntalo, P Aho, A Alba¨ck, E-M
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